Strategies for Entering the Biosimilars Market
The challenges and opportunities presented by the evolving biosimilars market in the regulated markets of the EU, US, and Japan, and the emerging markets of Brazil, Russia, India, China, and Korea are examined. Strategies employed by a diverse range of companies to enter the biosimilars market enable conclusions to be drawn on key factors for success in this sector.
Strategies for Entering the Biosimilars Market Report Summary The challenges and opportunities presented by the evolving biosimilars market in the regulated markets of the EU, US, and Japan, and the emerging markets of Brazil, Russia, India, China, and Korea are examined. Strategies employed by a diverse range of companies to enter the biosimilars market enable conclusions to be drawn on key factors for success in this sector. Features and benefits * Appreciate the regulatory, clinical, and commercial expertise required to participate in the biosimilars market segment. * Identify the main competitors in the biosimilars industry and gain insight into their differing biosimilar strategies. * Assess the benefits of partnerships and alliances in gaining market entry. * Identify key market and product opportunities, and evaluate regulatory hurdles. * Gain an insight into the main drivers of future market development. Request a Sample for or Inquire before buying the report @ http://www.reportsnreports.com/reports/144324-strategies-for-entering-the-biosimilars- market.html Highlights Sandoz, Teva, and Hospira have taken an early lead in the biosimilar market through a combination of in-house product development, acquisitions, and alliances. Their dominance in developed markets will progressively be challenged by regional generic players that forge partnerships with companies to compete on equal terms. South Korea’s growing biotech industry is in the vanguard of emerging markets poised to capture a share of the global market, with adoption of the EU regulatory model and strong government support. Rituximab is likely to become the first mAb biosimilar battleground, with emerging markets witnessing the first of many potential competitors. Experience with the first wave of biosimilars in Europe indicates that penetration of developed markets will be gradual, especially without the benefit of interchangeability with reference products. Biosimilars for acute short-term treatment will more readily acquire a greater share of the innovator’s sales than will those for long-term use. Major points covered in Table of Contents of this report include: About the author EXECUTIVE SUMMARY Overview of the biosimilars market Strategic considerations for biosimilar market entry Generics industry biosimilar strategies Research-based industry biosimilar strategies Role of contract service providers Identifying biosimilar opportunities Best practices for biosimilar market entry Appendix List Of Tables List Of Figures Explore Tables of content available in the report Strategies for Entering the Biosimilars Market Report Details: Published: December 2011 No.OF Pages: 115 Price: Single User License – US$ 3835 Corporate User License US$ 14381 Contact: Priyank Tiwari 7557 Rambler road, Suite 727, Dallas, TX 75231 Tel: +1-888-391-5441 firstname.lastname@example.org Visit our Market Research Blog @ http://www.reportsnreportsblog.com/ Connect With Us: